Zelboraf vs. dabranefib

Vicki to answer questionon  on switching to dabranefib after "Z" fails. This came up with visit on 6/19 with Dr. Anna  Pavlick. From her research her answer is that "D"  would  contiue to be just as effective as "Z"   to long time responders Says it works essentially the same but different…This is the take I got from her .It was not an in depht discussion.Thank God , I am still dong well on "Z". Hope more will post with their knowledge on subject.Beat the Beast.     Al

Vicki to answer questionon  on switching to dabranefib after "Z" fails. This came up with visit on 6/19 with Dr. Anna  Pavlick. From her research her answer is that "D"  would  contiue to be just as effective as "Z"   to long time responders Says it works essentially the same but different…This is the take I got from her .It was not an in depht discussion.Thank God , I am still dong well on "Z". Hope more will post with their knowledge on subject.Beat the Beast.     Al

Vicki to answer questionon  on switching to dabranefib after "Z" fails. This came up with visit on 6/19 with Dr. Anna  Pavlick. From her research her answer is that "D"  would  contiue to be just as effective as "Z"   to long time responders Says it works essentially the same but different…This is the take I got from her .It was not an in depht discussion.Thank God , I am still dong well on "Z". Hope more will post with their knowledge on subject.Beat the Beast.     Al

Randall, check out the thread "Hope for the Zelboraf Resistant" http://www.melanoma.org/community/mpip-melanoma-patients-information-page/hope-zelboraf-resistant It's about a different BRAF inhibitor that might work for people who failed Zelboraf.

As far as taking dabrafenib after Zelboraf, I don't think anyone knows the answer to that. The two drugs work on the same BRAF mutation but they have slightly different chemical structures. So one might work after the other or it might not. Unfortunately there have not been and are not likely to be any clinical trials testing that possibility. The two drugs are made by different manufacturers. A head-to-head clinical trial would mean that the 2 companies would have to cooperate and share their data. That will never happen. The lack of inter-company cooperation is a big problem even when trying to develop combination therapies like BRAF/MEK. That's a real problem for cancer patients.

Now that dabrafenib has been FDA approved (trade name Tafinalar) physicians might try Tafinalar after Zelboraf on their own and eventually publish papers about it. But that will take time. 

Randall, check out the thread "Hope for the Zelboraf Resistant" http://www.melanoma.org/community/mpip-melanoma-patients-information-page/hope-zelboraf-resistant It's about a different BRAF inhibitor that might work for people who failed Zelboraf.

As far as taking dabrafenib after Zelboraf, I don't think anyone knows the answer to that. The two drugs work on the same BRAF mutation but they have slightly different chemical structures. So one might work after the other or it might not. Unfortunately there have not been and are not likely to be any clinical trials testing that possibility. The two drugs are made by different manufacturers. A head-to-head clinical trial would mean that the 2 companies would have to cooperate and share their data. That will never happen. The lack of inter-company cooperation is a big problem even when trying to develop combination therapies like BRAF/MEK. That's a real problem for cancer patients.

Now that dabrafenib has been FDA approved (trade name Tafinalar) physicians might try Tafinalar after Zelboraf on their own and eventually publish papers about it. But that will take time. 

Randall, check out the thread "Hope for the Zelboraf Resistant" http://www.melanoma.org/community/mpip-melanoma-patients-information-page/hope-zelboraf-resistant It's about a different BRAF inhibitor that might work for people who failed Zelboraf.

As far as taking dabrafenib after Zelboraf, I don't think anyone knows the answer to that. The two drugs work on the same BRAF mutation but they have slightly different chemical structures. So one might work after the other or it might not. Unfortunately there have not been and are not likely to be any clinical trials testing that possibility. The two drugs are made by different manufacturers. A head-to-head clinical trial would mean that the 2 companies would have to cooperate and share their data. That will never happen. The lack of inter-company cooperation is a big problem even when trying to develop combination therapies like BRAF/MEK. That's a real problem for cancer patients.

Now that dabrafenib has been FDA approved (trade name Tafinalar) physicians might try Tafinalar after Zelboraf on their own and eventually publish papers about it. But that will take time. 

Conclusions: The clinical activity for 150/2 D+T combination is consistently superior in BRAFi-naive group vs BRAFi-resistant group in both Parts B and C. Dual MAPK blockade can delay clinical resistance to BRAF inhibition. However, once BRAFi resistance has occurred, the combination of BRAFi + MEKi is far less effective

Link:
http://meetinglibrary.asco.org/content/112346-132

Amy

Conclusions: The clinical activity for 150/2 D+T combination is consistently superior in BRAFi-naive group vs BRAFi-resistant group in both Parts B and C. Dual MAPK blockade can delay clinical resistance to BRAF inhibition. However, once BRAFi resistance has occurred, the combination of BRAFi + MEKi is far less effective

Link:
http://meetinglibrary.asco.org/content/112346-132

Amy

Conclusions: The clinical activity for 150/2 D+T combination is consistently superior in BRAFi-naive group vs BRAFi-resistant group in both Parts B and C. Dual MAPK blockade can delay clinical resistance to BRAF inhibition. However, once BRAFi resistance has occurred, the combination of BRAFi + MEKi is far less effective

Link:
http://meetinglibrary.asco.org/content/112346-132

Amy